Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO Phase 3 Study of Patisiran in TTR-mediated Polyneuropathy (FAP)
2013-002987-17Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2013
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR), familial amyloid polyneuropathy (FAP) and amyloid cardiomyopathy comparing Patisiran with Placebo (2 arms). Primary endpoint: Change in modified Neuropathy Impairment Score+7 (mNIS+7). Started Sep 2013; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)familial amyloid polyneuropathy (FAP)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2013-002987-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002987-17.